Sustoged 250 mg Euro Prime Farmaceuticals

Sustoged 250 mg Euro Prime Farmaceuticals: instructions for use

Sustoged 250 mg Euro Prime Farmaceuticals is a drug that combines 4 different forms of testosterone. It is available as a solution for injection. The mixture allows you to avoid frequent injections and provides a full testosterone effect. Sustoged 250 mg Euro Prime Farmaceuticals is a popular drug used for mass gain and many other effects.

What are the effects of Sustoged 250 mg Euro Prime Farmaceuticals?

Any testosterone ester has the same list of effects. The main difference between them is the absorption rate. The fact that the drug contains several esters allows them to be absorbed at different rates. Therefore, the level of hormones in the blood is kept at a constant level.

The main results of taking:

• increase in muscle mass by about 6 kg in 1 month;
• preservation of muscles (slowing down the process of their destruction);
• increased appetite;
• high libido

Testosterone has a beneficial effect on the condition of the joints. It increases the number of red blood cells in the blood. They in turn are carriers of nutrients and oxygen to muscle tissue and other organs. This affects the endurance and strength of the athlete. Golden Dragon 10mg Sustaged is most commonly taken in bulking cycles. It is not necessary to combine it with other steroids to obtain a pronounced result.

Contraindications and side effects

These drugs are contraindicated for persons under 18 years of age. They are also prohibited for people with neoplasms, diabetes and other serious diseases. Sustoged 250 mg Euro Prime Farmaceuticals is not recommended for women, as it has androgenic activity and causes virilisation. It is contraindicated for pregnant and lactating women.

Main side effects:

• gynecomastia;
• bloating;
• fat accumulation in abdomen and thighs;
• decreased testosterone production by the body;
• testicular atrophy.

All of these are resolved with Post Cycle Therapy. It is very important to take the course seriously and to consult a doctor.

Androgenic side effects can also occur: skin problems, baldness. There is an enlarged prostate. The course of admission should not be delayed, otherwise such unpleasant consequences are inevitable.

Admission regime: recommendations

The Mass Gathering course lasts approximately 10 weeks. During this time, you can gain up to 12 kg of muscle mass. Average dose: 250-500 mg. It is administered intramuscularly once a week. Very often, the gluteus muscle is chosen for this purpose.

Medications that will be needed during or after the course:

• gonadotropin to restore testosterone production;
• anti-estrogen to eliminate aromatisation and related problems.

Be sure to follow a diet that promotes a set of muscle mass. A specialist will help you calculate the exact dosage and work out a diet. Today you can take courses of combined preparations like Sustoged 250 mg Euro Prime Farmaceuticals and not harm your health.

List of references

1. Hormone Replacement Therapy (HRT):
   • Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95(6):2536-2559.
2. Effects of Testosterone Replacement:
   • Corona G, Rastrelli G, Maggi M. Diagnosis and treatment of late-onset hypogonadism: systematic review and meta-analysis of TRT outcomes. Best Pract Res Clin Endocrinol Metab. 2013;27(4):557-579.
3. Side Effects and Adverse Reactions:
   • Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363(2):109-122.
4. Testosterone and Cardiovascular Health:
   • Vigen R, O’Donnell CI, Barón AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310(17):1829-1836.
5. Testosterone in Aging and Age-Related Conditions:
   • Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of testosterone treatment in older men. N Engl J Med. 2016;374(7):611-624.